Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,038.27 +23.06 (+2.27%)

Official Closing Price Updated: 7:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

99 100 Next >

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

November 21, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Eli Lilly Joins Tech Players In The $1T Market Capitalization Club ↗

November 21, 2025

The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year.

Via Stocktwits

What's Going On With Novo Nordisk Stock? ↗

November 21, 2025

The management team conducted a cost-cutting effort that is likely to result in a more efficient business.

Via The Motley Fool

KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds

November 20, 2025

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a...

Via MarketMinute

Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 20, 2025

Via Benzinga

Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? ↗

November 20, 2025

Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

Via The Motley Fool

Correction and Clarification: Trifecta and Edward Fruitman, M.D., Do Not Maintain Any Contractual Relationship or Product Preference With Eli Lilly or LillyDirect®

November 20, 2025

November 20, 2025 -- The organization reiterates it has no partnership with Lilly and does not endorse or favor Eli Lilly products, including Zepbound®, in its weight-loss and medical services.

Via 24-7 Press Release

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗

November 19, 2025

Via MarketBeat

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 19, 2025

Via Benzinga

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War ↗

November 19, 2025

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs

November 19, 2025

Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new...

Via Barchart.com

Topics Intellectual Property

Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future

November 19, 2025

Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its...

Via MarketMinute

Eli Lilly Unusual Options Activity For November 19 ↗

November 19, 2025

Via Benzinga

Stock Split Watch: Could This Unstoppable Growth Stock Be Next? ↗

November 19, 2025

Don't wait for a stock split to buy the stock, though.

Via The Motley Fool

Healthcare Rotation Underway: 3 Stocks Leading the Charge ↗

November 19, 2025

Via MarketBeat

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

November 19, 2025

These stocks both have advanced in the double-digits in recent months.

Via The Motley Fool

2 High-Flying Stocks with Exciting Potential and 1 We Find Risky

November 18, 2025

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Via StockStory

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗

November 18, 2025

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

Via The Motley Fool

Can AI Drive Peloton's Comeback? ↗

November 18, 2025

The market is hopping with interesting news.

Via The Motley Fool

Topics Artificial Intelligence

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? ↗

November 18, 2025

Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%.

Via Benzinga

Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go ↗

November 18, 2025

Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.

Via Investor's Business Daily

Topics Government

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗

November 18, 2025

The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow.

Via Investor's Business Daily

Topics Government

Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗

November 18, 2025

Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this...

Via Benzinga

Topics Bankruptcy

1 Profitable Stock with Exciting Potential and 2 Facing Challenges

November 17, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3

November 17, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch

November 17, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE)

November 17, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy? ↗

November 17, 2025

Pfizer's weight management pipeline just got a boost.

Via The Motley Fool

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗

November 17, 2025

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

All News about Eli Lilly

Starting at $3.75/week.

Subscribe Today